Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: LDHA

Summary for LDHA

Gene information	Gene symbol	LDHA
	Ensembl ID	ENSG00000288299
	Entrez ID	3939
	Gene name	lactate dehydrogenase A
	Synonyms	NA
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: LDHA

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	-0.448456	2.48e-02
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	0.347531	5.04e-32
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	0.655692	0.00e+00
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	-0.882298	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.385761	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.434546	3.97e-09
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Progenitors	0.531597	5.22e-03
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	0.537212	1.78e-26
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.545524	1.39e-09
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.771717	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.348559	1.46e-31
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	-0.279622	8.36e-08
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.568802	1.23e-20
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	0.27456	2.27e-12
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	0.326388	8.47e-06
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	0.298713	2.64e-31
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.352629	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	-0.661247	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	0.441382	8.69e-07
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	-0.782855	5.76e-09
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	NK cells	-0.694843	1.78e-02
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.608974	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.923438	0.00e+00
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	-0.379987	4.62e-15
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.373629	2.82e-03
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.536617	4.58e-09
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.906777	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	1.41363	2.41e-12
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.607258	7.44e-31
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	NK cells	-0.2542	7.14e-12
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	-0.343897	6.07e-09
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	-0.966127	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD8+ T cells	-0.269886	3.22e-40
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	0.313299	4.71e-40
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	-0.361445	3.97e-26
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-0.783675	0.00e+00
GSE161195	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)	post	Malignant cells	0.504667	0.00e+00
GSE161195	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)	pre	Malignant cells	0.403334	0.00e+00
GSE158457	PDX cells	Cell line	Acute lymphoblastic leukemia	T-cell acute lymphoblastic leukemia (ALL)	Targeted therapy	dasatinib	NA	Malignant cells	-1.29775	0.00e+00
GSE149214	PC9 cell line	Cell line	Lung cancer	EGFR-mutated non-small cell lung cancer (NSCLC)	Targeted therapy	erlotinib	NA	Malignant cells	-0.26439	1.13e-04
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.716012	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.351607	0.00e+00
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.266778	1.57e-21
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.320432	8.67e-19
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.645532	0.00e+00
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.435176	3.59e-31
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.409147	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD4+ T cells	-0.354755	1.02e-03
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	-0.324325	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	-0.253494	6.16e-14
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD8+ T cells	-0.261468	3.81e-37
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-0.359077	2.71e-20
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	-0.316695	0.00e+00
GSE164897_Vem	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib	NA	Malignant cells	0.30282	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	0.702791	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	-0.670558	0.00e+00

Top

Expression of LDHA in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to LDHA

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Gene symbol	Mechanism
LDHA	Unusual Activation of Pro-survival Pathway

Page: 1

Top

MicroRNAs (miRNA) regulating LDHA

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
LDHA	hsa-miR-1208	95.5603	NM_001165416
LDHA	hsa-miR-4801	92.1861	NM_001165415
LDHA	hsa-miR-6751-5p	90.8411	NM_001165415
LDHA	hsa-miR-4731-3p	90.3968	NM_001165415
LDHA	hsa-miR-642b-5p	87.0958	NM_001165415
LDHA	hsa-miR-4778-3p	86.6396	NM_001165416
LDHA	hsa-miR-34a-5p	86.3673	NM_001165416
LDHA	hsa-miR-449a	86.3673	NM_001165416
LDHA	hsa-miR-6803-5p	85.4096	NM_001165415
LDHA	hsa-miR-33b-5p	85.2226	NM_001165415
LDHA	hsa-miR-33a-5p	85.2226	NM_001165415
LDHA	hsa-miR-6760-3p	85.2039	NM_001165416
LDHA	hsa-miR-6083	83.4249	NM_001165415
LDHA	hsa-miR-449b-5p	82.6412	NM_001165416
LDHA	hsa-miR-34c-5p	82.6412	NM_001165416
LDHA	hsa-miR-4317	81.2058	NM_001165415
LDHA	hsa-miR-6736-3p	80.6535	NM_001165416
LDHA	hsa-miR-4660	80.2698	NM_001165416

Page: 1

Top

Motifs and transcription factors (TFs) regulating LDHA

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
LDHA	taipale_tf_pairs__ETV2_DLX3_RSCGGAANNNNNNNTAATKR_CAP_repr	DLX3; ETV2 (directAnnotation).
LDHA	transfac_pro__M06362	ZNF730 (directAnnotation).
LDHA	metacluster_152.2	TWIST1 (directAnnotation).
LDHA	metacluster_22.20	MAFG (directAnnotation).
LDHA	metacluster_22.17	NFE2 (directAnnotation).
LDHA	transfac_pro__M06537	CTCFL (directAnnotation).
LDHA	hdpi__TEAD1	TEAD1 (directAnnotation).
LDHA	transfac_pro__M06764	ZNF112 (directAnnotation).
LDHA	metacluster_22.33	MAFK (inferredBy_Orthology).
LDHA	kznf__ZNF716_Imbeault2017_RP_RCADE	ZNF716 (directAnnotation).
LDHA	taipale_cyt_meth__KLF3_NRCCGCAGCCCN_FL_meth_repr	KLF3 (directAnnotation).
LDHA	transfac_pro__M06251	ZSCAN2 (inferredBy_Orthology).
LDHA	transfac_pro__M07448	ZBED1 (directAnnotation).
LDHA	transfac_pro__M05886	ZNF619 (directAnnotation).
LDHA	transfac_pro__M05702	ZNF20 (directAnnotation).
LDHA	taipale_tf_pairs__HOXB2_ETV4_ACCGGAAATGAN_CAP	ETV4; HOXB2 (directAnnotation).
LDHA	taipale__ELK1_full_NACTTCCGSCGGAARMN_repr	ELK1 (directAnnotation).
LDHA	homer__NCCACGTG_c-Myc	MYC (directAnnotation).
LDHA	taipale_tf_pairs__GCM1_ETV1_RTRNNGGCGGAAGTN_CAP	ETV1; GCM1 (directAnnotation).
LDHA	hdpi__ELF2	ELF2 (directAnnotation).
LDHA	metacluster_81.7	CREB1 (directAnnotation).
LDHA	taipale_cyt_meth__ZNF385D_NCGTCGCGACGN_eDBD_meth	ZNF385D (directAnnotation).
LDHA	transfac_pro__M05844	ZNF628 (inferredBy_Orthology).
LDHA	metacluster_160.2	FEZF1; FEZF2 (directAnnotation).
LDHA	transfac_pro__M05939	ZNF471 (directAnnotation).
LDHA	metacluster_102.2	ZBED1 (directAnnotation).
LDHA	transfac_pro__M01182	HINFP (directAnnotation).
LDHA	transfac_pro__M06991	MAFF (directAnnotation).
LDHA	taipale_tf_pairs__GCM1_HOXB13_NCCCGCANNMATAAA_CAP_repr	GCM1; HOXB13 (directAnnotation).
LDHA	hocomoco__E2F8_HUMAN.H11MO.0.D	E2F8 (directAnnotation).
LDHA	homer__TACGTGCV_HIF-1a	HIF1A (directAnnotation).
LDHA	transfac_pro__M05919	ZIM3 (directAnnotation).
LDHA	taipale_cyt_meth__ZBTB2_NTTTMCGGTWAN_eDBD	ZBTB2 (directAnnotation).
LDHA	kznf__CTCF_Transfac.7_Transfac	CTCF (directAnnotation).
LDHA	metacluster_144.9	SP2 (directAnnotation).
LDHA	transfac_pro__M06237	ZNF846 (directAnnotation).
LDHA	transfac_pro__M06464	ZNF679 (directAnnotation).
LDHA	metacluster_22.34	BACH2 (directAnnotation).
LDHA	taipale_tf_pairs__TEAD4_CLOCK_GGWATGNNNNNNNCACGTGN_CAP_repr	CLOCK; TEAD4 (directAnnotation).
LDHA	taipale_tf_pairs__HOXB2_ELF1_SMGGAAGTMRTTA_CAP	ELF1; HOXB2 (directAnnotation).
LDHA	metacluster_15.4	SMAD6 (directAnnotation). SMAD6 (inferredBy_Orthology).
LDHA	transfac_pro__M05711	ZNF37A (directAnnotation).
LDHA	transfac_pro__M06313	ZNF678 (directAnnotation).
LDHA	taipale_tf_pairs__FLI1_FOXI1_GAAAACCGAAAN_CAP_repr	FLI1; FOXI1 (directAnnotation).
LDHA	metacluster_22.16	BACH2 (directAnnotation).
LDHA	transfac_pro__M05916	ZNF407 (directAnnotation).
LDHA	taipale_tf_pairs__MYBL1_TBX21_AGGTGTGNCSGTTR_CAP_repr	MYBL1; TBX21 (directAnnotation).
LDHA	kznf__ZNF45_Imbeault2017_OM_RCADE	ZNF45 (directAnnotation).
LDHA	transfac_pro__M06234	ZNF91 (directAnnotation).
LDHA	transfac_pro__M06849	ZNF528 (directAnnotation).

Page: 1 2 3

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
LDHA	"Artenimol"	DB11638	small molecule
LDHA	"Copper"	DB09130	small molecule
LDHA	"Etheno-NAD"	DB02483	small molecule
LDHA	"NADH"	DB00157	small molecule
LDHA	"Nicotinamide"	DB02701	small molecule
LDHA	"Oxamic Acid"	DB03940	small molecule
LDHA	"Stiripentol"	DB09118	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."